Comparison of HRCT imaging features of ground glass opacity of COVID-19 and early-stage lung carcinoma
10.3760/cma.j.cn112434-20200302-00087
- VernacularTitle:COVID-19与早期肺癌磨玻璃样变的HRCT影像特征对比分析
- Author:
Guojun GENG
1
;
Xiaolei ZHU
;
Yanjun MI
;
Wei XIONG
;
Fan OU
;
Ning LI
;
Hongming LIU
;
Mengkun CAO
;
Chengqing DENG
;
Sien SHI
;
Xiuyi YU
;
Jie JIANG
Author Information
1. 厦门大学附属第一医院胸外科 361003
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2020;36(7):393-396
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the difference of HRCT imaging features between COVID-19 and the ground-glass opacity(GGO) lesion of early-stage lung carcinoma, standardize the diagnosis and treatment process of ground-glass opacity(GGO) degeneration during the epidemic.Methods:A total of 34 patients with diagnosed COVID-19 who confirmed by positive results of the new coronavirus nucleic acid test were collected as observation group 40 patients with pathologically diagnosed early-stage lung carcinoma whose preoperative HRCT examination showed pure ground glass lesions and received surgical intervention were recruited from the Department of Thoracic Surgery (The First Affiliated Hospital of Xiamen University) from January 2018 to December 2019 as the control group. The HRCT imaging features of these two groups of patients were compared and statistically analyzed.Results:The HRCT imaging features of the new type of COVID-19 showed significant difference by characteristics of multiple lesions, lesion rapid variation within 3 days, reticular pattern, vacuolar sign and clear boundary compared to the GGO lesion of early-stage lung carcinoma( P<0.05). The chinical and imaging characteristic the sex, age, with pleural effusion or not and the lesion location showed no significant difference between these 2 groups ( P>0.05). Conclusion:Contrast with inert early lung carcinoma lesions, COVID-19 disease developed rapidly. Imaging dynamic examination can provide evidences to distinguish Novel Coronavirus Pneumonia and early-stage lung carcinoma.
